Bristol-Myers (BMY) Wins Ruling Blocking Generic Plavix
More News related to BMY
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference
- Bristol-Myers Squibb (BMY) and Alder Biopharma Agree to Develop Rheumatoid Arthritis Treatment
- Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
- Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
More News related to SNY
- Morning Movers 11/11: NCST, SMI, MSN, CHLN, NLST, REGN Higher; TGIC, STS, CLWR, STV, MHR, MBLX Lower
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Bristol-Myers Squibb Co. (NYSE: BMY) and Sanofi-Aventis (NYSE: SNY) won a trial blocking generic competition on top selling blood-thinner Plavix. The court rejected Apotex\'s claim that the patent is invalid or unenforceable.
Related Categories
FDAStocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
